Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples.

[1]  L. Sánchez-Magraner,et al.  Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Chen,et al.  Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. , 2023, Medicine.

[3]  T. Mok,et al.  Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  C. Bestvina,et al.  Meeting an un-MET need: Targeting MET in non-small cell lung cancer , 2022, Frontiers in Oncology.

[5]  Tao Huang,et al.  State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer , 2022, Frontiers in Oncology.

[6]  M. Guo,et al.  MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome , 2022, Cancers.

[7]  C. Marquette,et al.  Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France) , 2022, Cancers.

[8]  Lingling Song,et al.  c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway , 2022, Journal of Molecular Medicine.

[9]  C. Marquette,et al.  Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer. , 2022, Lung cancer.

[10]  R. Heist,et al.  A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC , 2021, JTO clinical and research reports.

[11]  A. Nicholson,et al.  The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  J. Roth,et al.  Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer , 2021, Journal for ImmunoTherapy of Cancer.

[13]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Carbone,et al.  Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  H. Nechushtan,et al.  Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data , 2021, Oncoimmunology.

[16]  N. Reinmuth,et al.  Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  P. Pauwels,et al.  PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation , 2020, Virchows Archiv.

[18]  Vincent Alcazer,et al.  StatAid: An R package with a graphical user interface for data analysis , 2020, J. Open Source Softw..

[19]  L. Schwartz,et al.  A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). , 2020, Clinical lung cancer.

[20]  H. Groen,et al.  Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[21]  D. Rimm,et al.  Digital quantitative assessment of PD-L1 using digital spatial profiling , 2020, Laboratory Investigation.

[22]  M. Ladanyi,et al.  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Hung,et al.  Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. , 2020, American journal of cancer research.

[24]  M. Kris,et al.  Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[25]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[27]  K. Kerr,et al.  Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC , 2019, Nature Reviews Clinical Oncology.

[28]  J. Nemunaitis,et al.  First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Drilon,et al.  PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Copie-Bergman,et al.  Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms , 2017, PloS one.

[31]  Marius Ilie,et al.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients , 2016, Virchows Archiv.

[32]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[33]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  S. Serrano,et al.  MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC) , 2015, Oncotarget.

[35]  Jan Budczies,et al.  Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. , 2015, Lung cancer.

[36]  T. Zander,et al.  MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung , 2014, Clinical Cancer Research.

[37]  T. Holzer,et al.  Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET) , 2014, Histopathology.

[38]  X. Tan,et al.  Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures , 2014, PloS one.

[39]  I. Wistuba,et al.  Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit , 2014, Clinical Cancer Research.

[40]  T. Zander,et al.  Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer , 2012, Modern Pathology.

[41]  F. Hirsch,et al.  Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.